Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (31-40 of 350) with videos related to

Pageof 35
Sort By:
Alimentary Pharmacology & Therapeutics|March 25, 2024
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' replyMatthias Lenfant, Bram Verstockt, João Sabino, et al.
Journal of Crohn'S & Colitis|December 27, 2019
Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel DiseasesMichaël Somers, Peter Bossuyt, Marc Ferrante, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 14, 2005
Protein-losing enteropathy in Crohn's diseaseMarc Ferrante, Gert De Hertogh, Freddy Penninckx, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2024
Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel DiseaseDahham Alsoud, João Sabino, Marc Ferrante, et al.
Gut|September 15, 2020
Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's diseaseBram Verstockt, Liesbeth Boets, João Sabino, et al.
Journal of Crohn'S & Colitis|March 19, 2025
Serum extracellular RNAs as a noninvasive approach to differentiate inflammatory bowel disease subtypes: a proof-of-concept studySare Verstockt, João Sabino, Marc Ferrante, et al.
Alimentary Pharmacology & Therapeutics|October 16, 2023
The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitisMatthias Lenfant, Bram Verstockt, João Sabino, et al.
Alimentary Pharmacology & Therapeutics|February 13, 2024
Letter: Should ulcerative colitis be monitored more or less invasively? Authors' replyMatthias Lenfant, Bram Verstockt, João Sabino, et al.
Expert Review of Clinical Pharmacology|January 17, 2022
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseasesWannee Kantasiripitak, Zhigang Wang, Isabel Spriet, et al.
Current Gastroenterology Reports|November 12, 2009
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)Marc Ferrante, Geert D'Haens, Paul Rutgeerts, et al.
Pageof 35

Showing results (31-40 of 350) with videos related to

Sort By:
Pageof 35
Alimentary Pharmacology & Therapeutics|March 25, 2024
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' replyMatthias Lenfant, Bram Verstockt, João Sabino, et al.
Journal of Crohn'S & Colitis|December 27, 2019
Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel DiseasesMichaël Somers, Peter Bossuyt, Marc Ferrante, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 14, 2005
Protein-losing enteropathy in Crohn's diseaseMarc Ferrante, Gert De Hertogh, Freddy Penninckx, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2024
Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel DiseaseDahham Alsoud, João Sabino, Marc Ferrante, et al.
Gut|September 15, 2020
Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's diseaseBram Verstockt, Liesbeth Boets, João Sabino, et al.
Journal of Crohn'S & Colitis|March 19, 2025
Serum extracellular RNAs as a noninvasive approach to differentiate inflammatory bowel disease subtypes: a proof-of-concept studySare Verstockt, João Sabino, Marc Ferrante, et al.
Alimentary Pharmacology & Therapeutics|October 16, 2023
The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitisMatthias Lenfant, Bram Verstockt, João Sabino, et al.
Alimentary Pharmacology & Therapeutics|February 13, 2024
Letter: Should ulcerative colitis be monitored more or less invasively? Authors' replyMatthias Lenfant, Bram Verstockt, João Sabino, et al.
Expert Review of Clinical Pharmacology|January 17, 2022
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseasesWannee Kantasiripitak, Zhigang Wang, Isabel Spriet, et al.
Current Gastroenterology Reports|November 12, 2009
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)Marc Ferrante, Geert D'Haens, Paul Rutgeerts, et al.
Pageof 35